SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Stuki who wrote (45907)1/10/2006 8:22:53 PM
From: Mark Buczynski   of 120416
 
PVCT - the beauty of the product is that it is already FDA approved for other uses outside of cancel remediation. This little fact will speed clearance.

Also, and this is something they can't claim in the trial updates, is the ability of the solution to target and kill all tumors in the body - not just the tumors in which the solution is injected. This is the sleeper that will propel this company into the limelight. The major problem with cancer tumors is that they spread to other organs and areas in the body. Isolating all tumors is very problematic today. Once this happens survival is almost non-existent. PVCT has a solution.

There is an oncology conference in early June that I've heard Provecta will be presenting - I view this as the "on switch".

I'm just concerned that the company will simply get purchased by a tier-1 pharma before the real value of technology can be realized.

Mark
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News